152 related articles for article (PubMed ID: 36527875)
1. Neuroprotective effect of secukinumab against rotenone induced Parkinson's disease in rat model: Involvement of IL-17, HMGB-1/TLR4 axis and BDNF/TrKB cascade.
Mohamed YT; Salama A; Rabie MA; Abd El Fattah MA
Int Immunopharmacol; 2023 Jan; 114():109571. PubMed ID: 36527875
[TBL] [Abstract][Full Text] [Related]
2. Formoterol attenuated mitochondrial dysfunction in rotenone-induced Parkinson's disease in a rat model: Role of PINK-1/PARKIN and PI3K/Akt/CREB/BDNF/TrKB axis.
Khidr HY; Hassan NF; Abdelrahman SS; El-Ansary MR; El-Yamany MF; Rabie MA
Int Immunopharmacol; 2023 Dec; 125(Pt B):111207. PubMed ID: 37956489
[TBL] [Abstract][Full Text] [Related]
3. Sericin alleviates motor dysfunction by modulating inflammation and TrkB/BDNF signaling pathway in the rotenone-induced Parkinson's disease model.
Salari Z; Ashabi G; Fartoosi A; Fartoosi A; Shariatpanahi M; Aghsami M; Montazeri H; Kheradmand A
BMC Pharmacol Toxicol; 2023 Nov; 24(1):60. PubMed ID: 37936189
[TBL] [Abstract][Full Text] [Related]
4. Cilostazol novel neuroprotective mechanism against rotenone-induced Parkinson's disease in rats: Correlation between Nrf2 and HMGB1/TLR4/PI3K/Akt/mTOR signaling.
El-Sayed RM; Abdelaziz AM; Zaki HF; Abdel Rasheed NO
Int Immunopharmacol; 2023 Apr; 117():109986. PubMed ID: 37012873
[TBL] [Abstract][Full Text] [Related]
5. Oleuropein confers neuroprotection against rotenone-induced model of Parkinson's disease via BDNF/CREB/Akt pathway.
Singh R; Zahra W; Singh SS; Birla H; Rathore AS; Keshri PK; Dilnashin H; Singh S; Singh SP
Sci Rep; 2023 Feb; 13(1):2452. PubMed ID: 36774383
[TBL] [Abstract][Full Text] [Related]
6. PI3K/AKT signaling activation by roflumilast ameliorates rotenone-induced Parkinson's disease in rats.
Farid HA; Sayed RH; El-Shamarka ME; Abdel-Salam OME; El Sayed NS
Inflammopharmacology; 2024 Apr; 32(2):1421-1437. PubMed ID: 37541971
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways.
Abdelsalam RM; Safar MM
J Neurochem; 2015 Jun; 133(5):700-7. PubMed ID: 25752913
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Brain GTP Cyclohydrolase I Attenuates 3-Nitropropionic Acid-Induced Striatal Toxicity: Involvement of Mas Receptor/PI3k/Akt/CREB/ BDNF Axis.
Mustafa AM; Rabie MA; Zaki HF; Shaheen AM
Front Pharmacol; 2021; 12():740966. PubMed ID: 35002694
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin 1-7 ameliorates 6-hydroxydopamine lesions in hemiparkinsonian rats through activation of MAS receptor/PI3K/Akt/BDNF pathway and inhibition of angiotensin II type-1 receptor/NF-κB axis.
Rabie MA; Abd El Fattah MA; Nassar NN; El-Abhar HS; Abdallah DM
Biochem Pharmacol; 2018 May; 151():126-134. PubMed ID: 29428223
[TBL] [Abstract][Full Text] [Related]
10. Cilostazol Mediated Nurr1 and Autophagy Enhancement: Neuroprotective Activity in Rat Rotenone PD Model.
Hedya SA; Safar MM; Bahgat AK
Mol Neurobiol; 2018 Sep; 55(9):7579-7587. PubMed ID: 29429051
[TBL] [Abstract][Full Text] [Related]
11. Targeting ROS-Dependent AKT/GSK-3β/NF-κB and DJ-1/Nrf2 Pathways by Dapagliflozin Attenuates Neuronal Injury and Motor Dysfunction in Rotenone-Induced Parkinson's Disease Rat Model.
Arab HH; Safar MM; Shahin NN
ACS Chem Neurosci; 2021 Feb; 12(4):689-703. PubMed ID: 33543924
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effect of crocin against rotenone-induced Parkinson's disease in rats: Interplay between PI3K/Akt/mTOR signaling pathway and enhanced expression of miRNA-7 and miRNA-221.
Salama RM; Abdel-Latif GA; Abbas SS; El Magdoub HM; Schaalan MF
Neuropharmacology; 2020 Mar; 164():107900. PubMed ID: 31811872
[TBL] [Abstract][Full Text] [Related]
13. Effect of Bacille-Calmette-Guerin vaccine against rotenone-induced Parkinson's disease: Role of neuroinflammation and neurotransmitters.
Yedke NG; Soni D; Kumar P
Fundam Clin Pharmacol; 2024 Jun; 38(3):538-549. PubMed ID: 38041521
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factor 1 alpha and nuclear-related receptor 1 as targets for neuroprotection by albendazole in a rat rotenone model of Parkinson's disease.
Kandil EA; Sayed RH; Ahmed LA; Abd El Fattah MA; El-Sayeh BM
Clin Exp Pharmacol Physiol; 2019 Dec; 46(12):1141-1150. PubMed ID: 31408200
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab alleviates cognitive impairment by attenuating oxidative stress and neuronal apoptosis via the IL-17RA/AKT/ERK1/2 pathway in a rat model of sepsis.
Gao J; Wang Y; Ma S; Xu S; Chen M
Exp Neurol; 2023 Jan; 359():114263. PubMed ID: 36336029
[TBL] [Abstract][Full Text] [Related]
16. Oleanolic acid-based therapeutics ameliorate rotenone-induced motor and depressive behaviors in parkinsonian male mice via controlling neuroinflammation and activating Nrf2-BDNF-dopaminergic signaling pathways.
Pingale TD; Gupta GL
Toxicol Mech Methods; 2024 May; 34(4):335-349. PubMed ID: 38084769
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective action of agmatine in rotenone-induced model of Parkinson's disease: Role of BDNF/cREB and ERK pathway.
Bilge SS; Günaydin C; Önger ME; Bozkurt A; Avci B
Behav Brain Res; 2020 Aug; 392():112692. PubMed ID: 32479847
[TBL] [Abstract][Full Text] [Related]
18. Morin post-treatment surpassed calpeptin in ameliorating 3-NP-induced cortical neurotoxicity via modulation of glutamate/calpain axis, Kidins220, and BDNF/TrkB/AKT/CREB trajectory.
Mohamed OE; Abdallah DM; Fayez AM; Mohamed RA; El-Abhar HS
Int Immunopharmacol; 2023 Mar; 116():109771. PubMed ID: 36736222
[TBL] [Abstract][Full Text] [Related]
19. Hydroxysafflor Yellow A Improves Motor Dysfunction in the Rotenone-Induced Mice Model of Parkinson's Disease.
Wang T; Wang L; Li C; Han B; Wang Z; Li J; Lv Y; Wang S; Fu F
Neurochem Res; 2017 May; 42(5):1325-1332. PubMed ID: 28097465
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effect of anethole against rotenone induced non-motor deficits and oxidative stress in rat model of Parkinson's disease.
Vastegani SM; Khoshnam SE; Mansouri E; Hajipour S; Ghafouri S; Bakhtiari N; Sarkaki A; Farbood Y
Behav Brain Res; 2023 Feb; 437():114100. PubMed ID: 36075399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
